# QA102 Phase II Study in Subjects With Dry AMD

> **NCT05536752** · PHASE2 · COMPLETED · sponsor: **Smilebiotek Zhuhai Limited** · enrollment: 150 (actual)

## Conditions studied

- Dry Age-related Macular Degeneration

## Interventions

- **DRUG:** QA102/Placebo
- **DRUG:** QA102
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05536752
- **Lead sponsor:** Smilebiotek Zhuhai Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-22
- **Primary completion:** 2024-11-12
- **Final completion:** 2024-11-12
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2025-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05536752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05536752, "QA102 Phase II Study in Subjects With Dry AMD". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05536752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*